Aqua Bio Technology — Earnings Release 2013

Feb 12, 2014

Improved profits for Aqua Bio Technology

Improved profits for Aqua Bio Technology

Aqua Bio Technology ASA (Oslo Axess: ABT) today announced the 2013 preliminary

financial results. The Company had its best year ever.

Aqua Bio Technology had revenues of NOK 22.8 million last year, up from the

previous year's revenues of NOK 20.3 million. The EBITDA was NOK 7.8 million,

corresponding to an EBITDA margin of 34 per cent. The previous year's EBITDA was

NOK 8.0 million. The result before tax ended at NOK 2.8 million for 2013,

against NOK 0.9 million the previous year.

Aqua Bio Technology is still in an early phase of its commercial development,

and revenues will therefore fluctuate from quarter to quarter. ABT had revenues

of NOK 3.8 million in the fourth quarter, compared to NOK 3.4 million in the

corresponding quarter of the previous year. The EBITDA for the fourth quarter

was NOK -0.7, against NOK 0.2 million in the last quarter of 2012. The result

before tax for the fourth quarter was NOK -2.1 million, against NOK -2.7 million

in the same quarter of the previous year.

"Aqua Bio Technology saw progress in several key areas in 2013. Revenues grew,

our market position became stronger and a healthy cash flow made the Company

even more financially solid," said CEO Arvid Lindberg.

ABT's exclusivity partners on Aquabeautine XL(TM) both expanded their portfolios

of skin care products based on ABT's technology in 2013. Restorsea extended

their skincare line with new products, while Amway's new skin care series was

introduced in nine markets across Asia and the Pacific region.

Several new distributor agreements were signed in the fourth quarter. The new

agreements cover 16 countries totaling more than 300 million consumers,

primarily in Europe. These distributor agreements add to ABT's existing network

of distributors in Asia and the Americas.

Aqua Bio Technology describes the Company's outlook as promising.

"Existing contracts secure ABT's profitability over the next years. Increasing

sales volumes for Aquabeautine XL(TM) and expected revenues from new products

will over time contribute even further to the Company's profitability," Arvid

Lindberg said.

Aqua Bio Technology provides proprietary, marine based ingredients for the skin

care industry. The Company offers natural ingredients to the most rapidly

expanding segment in the fast growing cosmetics industry.

For further information, please call Arvid Lindberg, CEO, telephone

+47 9824 5410

Aqua Bio Technology ASA (ABT) develops, produces and markets patented

ingredients and technologies to the international cosmetic and skin care

industry. ABT's ingredients Aquabeautine XL(TM), Dermaclarine(TM) and Beauty

Propelline(TM) are marine solutions derived from the hatching fluid of salmon,

while Oceanx Oil in Serum is based on extract from seaweed. ABT is listed on the

Oslo Stock Exchange's Axess market.

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

[HUG#1761027]